{"id":3880,"date":"2025-12-16T15:47:37","date_gmt":"2025-12-16T20:47:37","guid":{"rendered":"https:\/\/halopharma.com\/?p=3880"},"modified":"2025-12-16T16:10:43","modified_gmt":"2025-12-16T21:10:43","slug":"halo-pharma-enhances-manufacturing","status":"publish","type":"post","link":"https:\/\/halopharma.com\/fr\/halo-pharma-enhances-manufacturing\/","title":{"rendered":"Halo Pharma Enhances Manufacturing Capabilities with Macro-Pactor Investment"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"3880\" class=\"elementor elementor-3880\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-793f20ed e-flex e-con-boxed e-con e-parent\" data-id=\"793f20ed\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-263ebe1 custom-post-subhead e-flex e-con-boxed e-con e-parent\" data-id=\"263ebe1\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-27b0f49 elementor-widget elementor-widget-text-editor\" data-id=\"27b0f49\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><strong><em>Whippany, NJ \u2013 December 16, 2025<\/em><\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-19f5d75 custom-post-subhead e-flex e-con-boxed e-con e-parent\" data-id=\"19f5d75\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-b527b42 elementor-widget elementor-widget-text-editor\" data-id=\"b527b42\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<ul>\n<li><em>New addition enhances manufacturing continuity and supports seamless progression from early-phase development to late-stage production<\/em><\/li>\n<li><em>Macro-Pactor\u00ae to be online in Q1 2026<\/em><\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-514c3c3e e-flex e-con-boxed e-con e-parent\" data-id=\"514c3c3e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-25314274 elementor-widget elementor-widget-text-editor\" data-id=\"25314274\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><\/p>\n<p>Halo Pharma, a leading CDMO specializing in pharmaceutical development and manufacturing services, is expanding its manufacturing capabilities at its Whippany, New Jersey facility with the addition of a Gerteis Macro-Pactor<sup>\u00ae<\/sup>, a versatile roller compactor that enhances the company\u2019s ability to manage complex formulations, improve process efficiency, and deliver consistent solid-dose pharmaceutical products. The investment reinforces Halo Pharma\u2019s position as a reliable partner for both development and commercial manufacturing as it allows for seamless scale up from Halo Whippany\u2019s Gerties Mini-Pactor<sup>\u00ae<\/sup> currently used for development, clinical and small scall commercial manufacturing.<\/p>\n<p>The Macro-Pactor is expected to be online in the first quarter of 2026. Its high throughput, superior dry-granulation performance, improved powder flow, and reduced variability will significantly expand Halo Pharma\u2019s dry-granulation capabilities. It will improve formulation flexibility, process predictability, and granule quality. This technology is especially beneficial for the development of moisture-sensitive APIs, high-drug-load formulations, poor-flowing powders, potent compounds, and modified-release products within Halo Pharma\u2019s portfolio.<\/p>\n<p>\u201cOne of the major advantages of adding the Macro-Pactor is that the process parameters established during early-phase development translates almost directly into larger batch sizes,\u201d says Satish Shetty, Senior Director, Product Development &amp; Technical Services at Halo Pharma. \u201cSince the equipment is engineered for both development and commercial throughput, it eliminates the typical disconnect between small-scale R&amp;D and large-scale manufacturing, reducing scale-up risk, timelines, and the need for reformulation.\u201d<\/p>\n<p>Shetty adds that the Macro-Pactor\u2019s closed, dust-contained design reduces operator exposure, minimizes product loss, and supports secure, regulatory-compliant handling. With fewer open processing steps, the system provides safer, more controlled operation for potent APIs and controlled substances.<\/p>\n<p>Beyond scale-up, the Macro-Pactor supports Halo Pharma\u2019s tech-transfer process. Its precise, data-rich control of critical process parameters enables smooth, low-risk transitions from lab-scale development to commercial manufacturing, strengthening the company\u2019s Quality by Design (QbD) efforts. Fully compatible with existing upstream and downstream equipment, the system ensures efficient end-to-end processing and strengthens collaboration across R&amp;D, process development, manufacturing, and quality teams.<\/p>\n<p>&#8220;Investing in the Macro-Pactor reinforces Halo Pharma\u2019s commitment to delivering high-quality, scalable manufacturing solutions for our clients. It ensures that they can confidently advance their programs with predictable outcomes and faster timelines,&#8221; says Lee Karras, Group Chief Executive for the Noramco Group, parent company of Halo Pharma.<\/p>\n<p>For more information about Halo Pharma, visit <a href=\"https:\/\/halopharma.com\/fr\/\">https:\/\/halopharma.com<\/a>.<\/p>\n<p><strong>About Halo Pharma<\/strong><br \/>Halo Pharma is a rapidly growing contract development and manufacturing organization (CDMO) that provides scientific and development expertise, as well as a wide spectrum of manufacturing services, from its locations in Whippany, New Jersey, USA and Montreal, Quebec, Canada to its international client base. Halo offers fully integrated capabilities in a variety of dosage forms including tablets, capsules, powders, liquids, creams, sterile and non-sterile ointments and suppositories. The company is registered to work with any of these dosages in the CI-CV DEA designations. Halo Pharma\u2019s capabilities in the areas of tech transfer, process and product development, production, scale-up\/validation and analytical method development allow us to partner with clients from development through commercialization or at any point along the way. For more information, please contact <a href=\"mailto:services@halopharma.com\">services@halopharma.com<\/a>.<\/p>\n<p><strong>Media Contact<\/strong><br \/>Resource Advantage<br \/>Dan Green<br \/><a href=\"mailto:dgreen@resourceadvantage.com\">dgreen@resourceadvantage.com<\/a><\/p>\n<p><strong>Company Contact<\/strong><br \/>Halo Pharma &amp; Woodstock Sterile Solutions<br \/>Stacy London<br \/><a href=\"mailto:Stacy.london@wssterile.com\">Stacy.london@wssterile.com<\/a><\/p>\n<p><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Whippany, NJ \u2013 December 16, 2025 New addition enhances manufacturing continuity and supports seamless progression from early-phase development to late-stage production Macro-Pactor\u00ae to be online in Q1 2026 Halo Pharma, a leading CDMO specializing in pharmaceutical development and manufacturing services, is expanding its manufacturing capabilities at its Whippany, New Jersey facility with the addition of [&hellip;]<\/p>\n","protected":false},"author":25,"featured_media":3638,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[6],"tags":[],"class_list":["post-3880","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=3880"}],"version-history":[{"count":5,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3880\/revisions"}],"predecessor-version":[{"id":3885,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3880\/revisions\/3885"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/media\/3638"}],"wp:attachment":[{"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=3880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=3880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=3880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}